Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02175225 · ClinicalTrials.gov registry record · Phase 2
Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial
A Phase 2 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 294
- Enrollment target
NCT02175225 is a Phase 2 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 294 participants.
The verdict
NCT02175225, a Phase 2 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 294 participants
- Enrollment target
Study Summary
The investigators hypothesize that treatment with the iron chelator, Deferoxamine Mesylate, improves the outcome of patients with brain hemorrhage. The purpose of this study is to determine whether treatment with Deferoxamine Mesylate is of sufficient promise to improve outcome before pursuing a larger clinical trial to examine its effectiveness as a treatment for intracerebral hemorrhage.
Interventions
- DRUG Deferoxamine Mesylate
- DRUG Placebo (for Deferoxamine Mesylate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 294 participants |
| Start Date | 2014-10 |
| Est. Completion | 2018-05-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02175225
The ClinicalTrials.gov registry entry for NCT02175225 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 294 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Deferoxamine Mesylate is the first listed.
NCT02175225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02175225 about?
NCT02175225 is a clinical study titled "Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial". The investigators hypothesize that treatment with the iron chelator, Deferoxamine Mesylate, improves the outcome of patients with brain hemorrhage. The purpose of this study is to determine whether treatment with Deferoxamine Mesylate is of sufficient promise to improve outcome before pursuing a la...
What is the current status of trial NCT02175225?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 294 participants. The study started on 2014-10. Estimated completion is 2018-05-30.
What interventions are being tested in trial NCT02175225?
The interventions under investigation include: Deferoxamine Mesylate (DRUG), Placebo (for Deferoxamine Mesylate) (DRUG).
Who is sponsoring clinical trial NCT02175225?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.